文献速递淋巴瘤

他法西他单抗联合或不联合来那度胺加入一线R-CHOP方案治疗弥漫性大B细胞淋巴瘤的安全性与疗效:1b期First-MIND研究

Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
PubMed 文献 · Blood · 2023-01-01

这项开放标签1b期First-MIND研究评估了他法西他单抗联合R-CHOP方案(加或不加来那度胺)一线治疗弥漫性大B细胞淋巴瘤的安全性和初步疗效。2019年12月至2020年8月,66例未经治疗的弥漫性大B细胞淋巴瘤患者(国际预后指数2-5)随机分配至R-CHOP-他法西他单抗组(T组)或R-CHOP-他法西他单抗-来那度胺组(T/L组),每组33例,治疗6个周期。两组均观察到可控的安全性和有希望的疗效信号。

要点

  • 所有患者均发生至少1起治疗中出现的不良事件,多为1级或2级。
  • T组和T/L组的3级及以上中性粒细胞减少发生率分别为57.6%和84.8%,血小板减少分别为12.1%和36.4%。
  • 治疗结束时总缓解率T组为75.8%(完全缓解72.7%),T/L组为81.8%(完全缓解66.7%)。

核心结论

  • 两组均观察到可控的安全性和有希望的疗效信号。
  • 他法西他单抗联合来那度胺加入R-CHOP方案的潜在获益正在3期frontMIND研究(NCT04824092)中探索。

研究设计与样本

  • 开放标签、1b期First-MIND研究,2019年12月至2020年8月筛查83例未经治疗的弥漫性大B细胞淋巴瘤成人患者(国际预后指数2-5),66例随机分配(每组33例)至R-CHOP-他法西他单抗组(T组)或R-CHOP-他法西他单抗-来那度胺组(T/L组),治疗6个周期。
  • 主要终点为安全性;次要终点包括治疗结束时总缓解率和完全缓解率。

主要发现

  • 所有患者均发生至少1起治疗中出现的不良事件,多为1级或2级。
  • 3级及以上中性粒细胞减少和血小板减少分别发生于T组57.6%和12.1%的患者,以及T/L组84.8%和36.4%的患者。
  • 两组非血液学毒性发生率相似。
  • 两组R-CHOP平均相对剂量强度均≥89%。
  • 治疗结束时总缓解率T组为75.8%(完全缓解72.7%),T/L组为81.8%(完全缓解66.7%);跨访视最佳总缓解率分别为90.0%和93.9%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anti-CD19 immunotherapy tafasitamab is used in combination with lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant. Open-label, phase 1b, First-MIND study assessed safety and preliminary efficacy of tafasitamab + R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) ± lenalidomide as first-line therapy in patients with DLBCL. From December 2019 to August 2020, 83 adults with untreated DLBCL (International Prognostic Index 2-5) were screened and 66 were randomly assigned (33 per arm) to R-CHOP-tafasitamab (arm T) or R-CHOP-tafasitamab-lenalidomide (arm T/L) for 6 cycles. Primary end point was safety; secondary end points included end-of-treatment (EoT) overall response rate (ORR) and complete response (CR) rate. All patients had ≥1 treatment-emergent adverse event, mostly grade 1 or 2. Grade ≥3 neutropenia and thrombocytopenia occurred, respectively, in 57.6% and 12.1% (arm T) and 84.8% and 36.4% (arm T/L) of patients. Nonhematologic toxicities occurred at similar rates among arms. R-CHOP mean relative dose intensity was ≥89% in both arms. EoT ORR was 75.8% (CR 72.7%) in arm T and 81.8% (CR 66.7%) in arm T/L; best ORR across visits was 90.0% and 93.9%. Eighteen-month duration of response and of CR rates were 72.7% and 74.5% (arm T) and 78.7% and 86.5% (arm T/L); 24-month progression-free and overall survival rates were 72.7% and 90.3% (arm T) and 76.8% and 93.8% (arm T/L). Manageable safety and promising signals of efficacy were observed in both arms. Potential benefit of adding tafasitamab + lenalidomide to R-CHOP is being investigated in phase 3 frontMIND (NCT04824092). This study is registered at www.clinicaltrials.gov as #NCT04134936.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Belada D, Kopeckova K, Bergua Burgues JM, et al. Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study. Blood. 2023. PMID: 37369099. doi:10.1182/blood.2023020637

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。